EU/3/04/227

Table of contents

About

On 20 October 2004, orphan designation (EU/3/04/227) was granted by the European Commission to Orphix Consulting GmbH, Germany, for 1, 1'-[1,4-phenylenebis (methylene)]-bis-1,4,8,11- tetraazacyclotetradecane for treatment to mobilize progenitor cells prior to stem cell transplantation. The sponsorship was transferred to Genzyme Europe BV, the Netherlands, in June 2007.

l, 1'-[1,4-phenylenebis (methylene)]-bis-1,4,8,11- tetraazacyclotetradecane has been authorised in the EU as Mozobil since 31 July 2009.

The sponsor’s address was updated in December 2018.

Key facts

Active substance
1, 1'-[1,4-Phenylenebis (methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
Medicine name
Mozobil
Disease / condition
Treatment to mobilize progenitor cells prior to stem cell transplantation
Date of first decision
20/10/2004
Outcome
Positive
EU designation number
EU/3/04/227

Sponsor's contact details

Genzyme Europe BV
Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands
Tel. +31 20 245 4000
E-mail: eumedinfo.gz@sanofi.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating
Average
1 rating